Translational Development Acquisition Corp.
NASDAQ:TDACShell Companies
-$0.01 today
- Market cap
- $267.99M
- Beta
- 0.01
- P/E (TTM)
- 29.8
- EPS (TTM)
- $0.36
Volume 0.47M
Average 0.10M
TDAC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Translational Development Acquisition Corp.NASDAQ: TDAC
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 88.1% from a year ago
Cash & equivalents stood at $24.63K at the end of Q1 FY2026, down 88.1% from a year earlier and down 17.3% from the prior quarter. Over 3 fiscal years it compounded at +137.4% a year.
Context
- Cash & equivalents amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -88.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 29.79K USD
- Year-over-year change
- -93.2%
- 3-year CAGR
- +137.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.79K | -93.2% |
| FY2024 | 2024-12-31 | 438.17K | +21581.0% |
| FY2023 | 2023-12-31 | 2.02K | -9.2% |
| FY2022 | 2022-12-31 | 2.23K | — |
Cash & Equivalents vs competitors
How TDAC compares with its peers on the latest reported figures
- TDAC's Mar 2026 cash & equivalents of $24.63K is the 5th highest of the 7 companies compared; the peer median is $218.95K.
- Its year-over-year change of -88.1% is the 3rd highest of 5, against a peer median of -78.6%.
- Cash & equivalents amounts to 0.0% of total assets for TDAC, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $653.38K | — | -0.8% | 0.3% | |
NTWONewbury Street II Acquisition Corp | Mar 2026 | $497.39K | -55.9% | — | 0.3% |
| Mar 2026 | $412.91K | -66.2% | +95.5% | 0.2% | |
| Mar 2026 | $25K | -90.9% | — | 0.0% | |
| Mar 2026 | $24.63K | -88.1% | +137.4% | 0.0% | |
MACIMelar Acquisition Corp. I | Mar 2026 | $14.21K | -98.0% | — | 0.0% |
| Jun 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding TDAC) | $218.95K | -78.6% | +47.4% | 0.1% | |
Competitors are the stored peer set for TDAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Translational Development Acquisition Corp.
NASDAQ:TDAC
Intrinsic Alpha fair value
Locked
Current Price
$10.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.